Company Overview - RAPT Therapeutics, Inc. is a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing, and commercializing novel therapies for patients with inflammatory and immunological diseases [4] Key Appointment - Jessica Savage, M.D., M.H.S., has been appointed as Vice President of Clinical Development to oversee the development of RPT904, a novel monoclonal antibody targeting free human immunoglobulin E (IgE) [1][2] - Dr. Savage brings extensive experience in food allergy and allergic diseases, having held significant roles in clinical development at prestigious institutions and companies [3] Product Development - RAPT plans to advance RPT904 into a Phase 2b clinical trial for food allergy in the second half of 2025, aiming to generate data that differentiates RPT904 as a therapeutic option [2] - The initial focus for RPT904 will be on food allergy and chronic spontaneous urticaria (CSU), addressing a significant unmet need in these areas [1][2] Expertise and Background of Dr. Savage - Dr. Savage has a strong background in clinical development, having worked on global programs and held faculty positions at Harvard Medical School and Johns Hopkins University [3] - Her previous roles include Senior Medical Director at Alexion, where she led clinical development strategies for various conditions, showcasing her capability to drive RPT904's development [3]